Last10K.com

Bellerophon Therapeutics, Inc. (BLPH) SEC Filing 10-K Annual report for the fiscal year ending Sunday, December 31, 2017

Bellerophon Therapeutics, Inc.

HISTORY TOOLS
CIK: 1600132 Ticker: BLPH


Exhibit 99.1
blphlogoa25.jpg

Bellerophon Provides Business Update and Reports Fourth Quarter and Full-Year 2017 Financial Results

Warren, NJ, March 15, 2018 -
Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the fourth quarter and full-year ended December 31, 2017.

“I am pleased to report continued progress in our clinical development programs evaluating INOpulse® to treat pulmonary hypertension in a wide range of unmet chronic diseases,” said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. “Our most advanced program, INOvation-1, a Phase 3 study for pulmonary arterial hypertension (PAH), is more than 50% enrolled, and an interim analysis is planned for mid-2018, with availability of top-line data for the complete study anticipated around the end of the year. In addition, we have randomized the first patient in our Phase 2b study evaluating INOpulse in pulmonary hypertension associated with interstitial lung disease (PH-ILD) including idiopathic pulmonary fibrosis (PH-IPF). We expect top-line results from this study by the end of the year. Recently, we announced positive results from our Phase 2 study in pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) and look forward to continuing the development of INOpulse in this devastating unmet medical need.”

“Importantly, our robust clinical development program is supported by a strong balance sheet, as we ended 2017 with more than $31.8 million in cash, cash equivalents and marketable securities. The upcoming year has the potential to be transformative for Bellerophon, with data expected in our PAH and PH-ILD programs, as well as anticipated further progress in our PH-COPD clinical development program. We are excited about these opportunities and remain focused on developing first-in-class therapies for patients suffering from serious chronic orphan pulmonary diseases in order to continue building long-term shareholder value,” concluded Mr. Tenenbaum.

Key Recent Highlights

•
PAH: Enrollment in the Phase 3 INOvation-1 study evaluating INOpulse® in patients with PAH now exceeds 100 patients, representing more than half of the anticipated enrollment. As previously agreed with the U.S. Food and Drug Administration (FDA), an interim analysis of this study will be performed by the Data Monitoring Committee when half of the subjects complete the 16-week blinded treatment phase. The interim analysis will determine if the study should be stopped early for efficacy or futility, continued as planned, or if the study size should be increased. The Company anticipates the readout of the interim analysis in mid-2018, and the availability of top-line data from the full study around the end of 2018.

•
PH-ILD: Following positive results in its Phase 2a study in PH-IPF, Bellerophon has initiated and randomized the first patient in a Phase 2b study evaluating INOpulse to assess the safety and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in patients with PH-ILD. A total of 40 subjects will be randomized in the double-blind, placebo-controlled clinical study, including patients with idiopathic pulmonary fibrosis. The primary endpoint of the study is the change in 6 Minute Walk Distance (6MWD) and the study includes several additional endpoints, including improvement in right ventricular function. Top-line results from this study are expected to be available by the end of 2018.

1
The following information was filed by Bellerophon Therapeutics, Inc. (BLPH) on Thursday, March 15, 2018 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Bellerophon Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bellerophon Therapeutics, Inc..

Continue

Assess how Bellerophon Therapeutics, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bellerophon Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Rating

Learn More
Bullish Bearish Neutral
Filter Sentiment:
All
Positive
Negative
Filter Category:
All
Financial
Revenue
Other
Filter Subcategory:
All
Expense
Product
Shares
Dividend
Income
Debt
Other
Inside Bellerophon Therapeutics, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Changes In Stockholders???/members' Equity (deficiency In Assets)
Consolidated Statements Of Changes In Stockholders???/members' Equity (deficiency In Assets) (parenthetical)
Consolidated Statements Of Comprehensive Loss
Consolidated Statements Of Operations
Commitments And Contingencies
Commitments And Contingencies (narrative) (details)
Commitments And Contingencies (operating Lease Obligations) (details)
Commitments And Contingencies (tables)
Commitments And Contingencies (tsa And The 2015 Services Agreement) (details)
Common Stock Warrants
Common Stock Warrants (narrative) (details)
Common Stock Warrants (tables)
Common Stock Warrants (warrant Activity) (details)
Fair Value Measurements
Fair Value Measurements (hierarchy) (details)
Fair Value Measurements (tables)
Fair Value Measurements (weighted Average Assumptions) (details)
Income Taxes
Income Taxes (deferred Tax Assets And Liabilities) (details)
Income Taxes (narrative) (details)
Income Taxes (reconciliation Of Effective Income Tax Rate) (details)
Income Taxes (tables)
Liquidity
Liquidity (narrative) (details)
Liquidity (schedule Of Prepayments) (details)
Liquidity (tables)
Marketable Securities
Marketable Securities (amortized Cost, Gains/losses And Fair Value) (details)
Marketable Securities (maturities) (details)
Marketable Securities (tables)
Net Loss Per Share
Net Loss Per Share (details)
Organization And Nature Of The Business
Organization And Nature Of The Business (details)
Property And Equipment
Property And Equipment (details)
Property And Equipment (tables)
Quarterly Financial Data (unaudited)
Quarterly Financial Data (unaudited) (details)
Quarterly Financial Data (unaudited) (tables)
Restructuring Charges
Restructuring Charges (details)
Restructuring Charges (tables)
Stock-based Compensation
Stock-based Compensation (allocation Of Period Costs) (details)
Stock-based Compensation (fair Value Of Options Issued) (details)
Stock-based Compensation (ikaria Equity Incentive Plan) (details)
Stock-based Compensation (narrative) (details)
Stock-based Compensation (option Activity) (details)
Stock-based Compensation (restricted Stock Activity) (details)
Stock-based Compensation (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)

Material Contracts, Statements, Certifications & more

Bellerophon Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32: Section 1350 Certification
Ticker: BLPH
CIK: 1600132
Form Type: 10-K Annual Report
Accession Number: 0001600132-18-000034
Submitted to the SEC: Thu Mar 15 2018 4:30:00 PM EST
Accepted by the SEC: Thu Mar 15 2018
Period: Sunday, December 31, 2017
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/blph/0001600132-18-000034.htm